EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Synthesis and Clinical Application of Small‐Molecule Drugs Approved by FDA in 2025

Liang Chang, Min Wang, Huijie Zhang, Zhen Li, Zixuan Song iD, Lijie Zhao iD, Fengli Jiang, Jiao Wang, Yuan Quan

Medicinal Research Reviews · 2026

DOI: 10.1002/med.70064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2026. Verfasst von Liang Chang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval, Small Molecule Libraries. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 117 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2025, the U.S. Food and Drug Administration (FDA) continued to advance therapeutic innovation by approving a diverse range of novel drugs. According to the FDA's 2025 Novel Drug Approvals list, 46 new drugs received approval, including both new chemical entities such as Ziftomenib, Sevabertinib, Zoliflodacin, and Gepotidacin, as well as new biologics. These approvals cover a wide range of therapeutic areas, including oncology, rare genetic diseases, infectious diseases, cardiovascular diseases, and immunomodulation. A significant proportion of the approved products navigated accelerated or priority review pathways, reflecting their potential impact on unmet medical needs. This review provides a comprehensive overview of the synthetic routes and clinical applications of FDA‐approved small‐molecule drugs in 2025, aiming to inspire future development in drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationDrug ApprovalSmall Molecule LibrariesUnited StatesHumansDrug Discovery

Stichwörter der Autor:innen

2025FDAclinical applicationssynthesis

Substanzen

Small Molecule Libraries

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
  • The Rogel Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Anesthesiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.

ORCID-Profile: Zixuan Song, Lijie Zhao

Zitieren

APA

Chang, L., Wang, M., Zhang, H., Li, Z., Song, Z., Zhao, L., Jiang, F., Wang, J., & Quan, Y. (2026). Synthesis and Clinical Application of Small‐Molecule Drugs Approved by FDA in 2025. Medicinal Research Reviews. https://doi.org/10.1002/med.70064

Vancouver

Chang L, Wang M, Zhang H, Li Z, Song Z, Zhao L, et al. Synthesis and Clinical Application of Small‐Molecule Drugs Approved by FDA in 2025. Medicinal Research Reviews. 2026. doi:10.1002/med.70064

BibTeX
@article{Chang2026,
  author = {Chang, Liang and Wang, Min and Zhang, Huijie and Li, Zhen and Song, Zixuan and Zhao, Lijie and Jiang, Fengli and Wang, Jiao and Quan, Yuan},
  title = {Synthesis and Clinical Application of Small‐Molecule Drugs Approved by FDA in 2025},
  journal = {Medicinal Research Reviews},
  year = {2026},
  doi = {10.1002/med.70064}
}
Kostenlos starten →